All In Biotech

Drug Trial Radar · NCT00671749

Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris

A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris

Last checked: Nov 20, 2026Latest source record: Aug 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

100

Actual

Start

Dec 2007

Primary completion

Aug 2008

Study completion Aug 2008

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
May 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to determine the efficacy and safety of 12 week treatment with Differin® Gel 0.3% applied in the evening, in combination with Duac® (Clindamycin/Benzoyl Peroxide Gel) applied in the morning, in Subjects with Acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • adapalene gel, 0.3%Drug

    Applied once daily at bedtime

  • clindamycin/benzoyl peroxide gelDrug

    Applied once daily in the morning

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Total Lesion CountsTime frame: 6 and 12 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Center for Dermatology and Laser Surgery

    Sacramento, California

  • Derm Research, P.L.L.C.

    Louisville, Kentucky

  • Brodell Medical

    Warren, Ohio

  • Northwest Cutaneous Research Specialists

    Portland, Oregon

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.